IPSFF1S deltab2m
RCPCMi007-A-1
General
Cell Line |
|
| hPSCreg Name | RCPCMi007-A-1 |
| Alternative name(s) |
IPSFF1S deltab2m
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Last update | 5th July 2021 |
| User feedback | |
Provider |
|
| Generator | Federal State Budgetary Institution Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency (RCPCM) |
External Databases |
|
| BioSamples | SAMEA8944453 |
| Cellosaurus | CVCL_A8DK |
| CLO | CLO_0103326 |
| Wikidata | Q107116727 |
General Information |
|
| Publications |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA8944452 |
Ethics
Also have a look at the ethics information for the parental line
RCPCMi007-A
.
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
RCPCMi007-A.
|
|
Reprogramming method |
|
| Vector type | None |
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | cloning on Tesr1 media for 4-5 passages. the main selection criterion morphology and stable karyotype |
| Derived under xeno-free conditions |
Yes |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
TrypLE
|
| CO2 Concentration | 5 % |
| Medium | TeSR™ E8™ |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| DPPA-5 |
Yes |
|
||||
| NANOG |
Yes |
|||||
| SALL-4 |
Yes |
|||||
| SOX2 |
Yes |
|
||||
| SSEA-4 |
Yes |
|||||
| TRA 1-81 |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
Morphology pictures
фазовый контраст.tif
phase contrast microscopy
Differentiation Potency
In vitro spontaneous differentiation
| Marker | Expressed |
| HNF4A – hepatocyte nuclear factor 4 alpha |
Yes |
Morphology
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46XX
Passage number: 13
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Genetic modifications not related to a disease |
|
Login to share your feedback, experiences or results with the research community.